<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) is now an established form of intensive insulin treatment </plain></SENT>
<SENT sid="1" pm="."><plain>It is pertinent to ask, however, if multiple daily injection (<z:chebi fb="5" ids="53218">MDI</z:chebi>) regimens based on new long-acting insulin analogs such as glargine and detemir have now replaced the need for CSII </plain></SENT>
<SENT sid="2" pm="."><plain>In type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, CSII reduces the frequency of severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> compared with isophane-based <z:chebi fb="5" ids="53218">MDIs</z:chebi>, but the rate of severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> is usually similar on glargine- or detemir-based <z:chebi fb="5" ids="53218">MDIs</z:chebi> compared with isophane-based <z:chebi fb="5" ids="53218">MDIs</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>CSII reduces A1C and glycemic variability compared with isophane-based <z:chebi fb="5" ids="53218">MDIs</z:chebi>; but glargine and detemir do not improve A1C or variability in many patients, particularly those who are prone to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Head-to-head comparisons of CSII with <z:chebi fb="5" ids="53218">MDI</z:chebi> based on glargine indicate lower A1C, <z:chebi fb="0" ids="24103">fructosamine</z:chebi>, or <z:chebi fb="105" ids="17234">glucose</z:chebi> levels on CSII </plain></SENT>
<SENT sid="5" pm="."><plain>It can be concluded that long-acting insulin analogs have not yet replaced the need for insulin pump therapy in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, and CSII is the best current therapeutic option for some type 1 diabetic subjects </plain></SENT>
<SENT sid="6" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, CSII and <z:chebi fb="5" ids="53218">MDI</z:chebi> produce similar glycemic control, although there is little study of <z:chebi fb="5" ids="53218">MDI</z:chebi> based on long-acting analogs compared with pumps </plain></SENT>
<SENT sid="7" pm="."><plain>It is possible that CSII will be beneficial in selected patient groups with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but this requires further study </plain></SENT>
</text></document>